JP2005535289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535289A5 JP2005535289A5 JP2003569776A JP2003569776A JP2005535289A5 JP 2005535289 A5 JP2005535289 A5 JP 2005535289A5 JP 2003569776 A JP2003569776 A JP 2003569776A JP 2003569776 A JP2003569776 A JP 2003569776A JP 2005535289 A5 JP2005535289 A5 JP 2005535289A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- sequence
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 208000030507 AIDS Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 230000029812 viral genome replication Effects 0.000 claims 5
- 230000003321 amplification Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35739102P | 2002-02-15 | 2002-02-15 | |
| US38024902P | 2002-05-13 | 2002-05-13 | |
| US39130602P | 2002-06-25 | 2002-06-25 | |
| US40629702P | 2002-08-27 | 2002-08-27 | |
| US41200702P | 2002-09-19 | 2002-09-19 | |
| US41750802P | 2002-10-10 | 2002-10-10 | |
| US43231802P | 2002-12-10 | 2002-12-10 | |
| PCT/US2003/004246 WO2003070883A2 (en) | 2002-02-15 | 2003-02-13 | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535289A JP2005535289A (ja) | 2005-11-24 |
| JP2005535289A5 true JP2005535289A5 (enExample) | 2006-03-30 |
Family
ID=27761699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569776A Pending JP2005535289A (ja) | 2002-02-15 | 2003-02-13 | １４１４分子、１４８１分子、１５５３分子、３４０２１分子、１７２０分子、１６８３分子、１５５２分子、１６８２分子、１６７５分子、１２８２５分子、９９５２分子、５８１６分子、１０００２分子、１６１１分子、１３７１分子、１４３２４分子、１２６分子、２７０分子、３１２分子、１６７分子、３２６分子、１８９２６分子、６７４７分子、１７９３分子、１７８４分子または２０４５分子を用いて、ａｉｄｓおよびｈｉｖ関連障害を処置するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20030216288A1 (enExample) |
| EP (1) | EP1474535A4 (enExample) |
| JP (1) | JP2005535289A (enExample) |
| AU (1) | AU2003215190A1 (enExample) |
| WO (1) | WO2003070883A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2838742B1 (fr) * | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| WO2005101003A1 (en) * | 2004-04-13 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with purinoceptor 4 type y (p2y4) |
| WO2006010497A2 (en) * | 2004-07-28 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with choline kinase (chk) |
| EP2044110A2 (en) * | 2006-07-11 | 2009-04-08 | Urban Scheuring | Compositions and methods for inhibiting hiv infections by inhibiting lerepo4 and glipr |
| US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
| US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| JP2016517395A (ja) | 2013-02-28 | 2016-06-16 | ニュー・ヘルス・サイエンシーズ・インコーポレイテッドＮｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． | 血液処理のためのガス枯渇化およびガス添加デバイス |
| IL299978B2 (en) | 2015-03-10 | 2024-08-01 | Hemanext Inc | Single-use oxygen reduction kits, devices and methods for their use |
| JP7175611B2 (ja) | 2015-04-23 | 2022-11-21 | ヘマネクスト インコーポレイテッド | 嫌気性血液保存容器 |
| ES3042959T3 (en) | 2015-05-18 | 2025-11-24 | Hemanext Inc | Methods for the storage of whole blood, and compositions thereof |
| CA3025619A1 (en) | 2016-05-27 | 2017-11-30 | New Health Sciences, Inc. | Anaerobic blood storage and pathogen inactivation method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6784400A (en) * | 1999-08-17 | 2001-03-13 | Glaxo Group Limited | Treatment of metastatic disease |
| US6482935B1 (en) * | 2000-05-24 | 2002-11-19 | Applera Corporation | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| US6492156B1 (en) * | 2001-10-31 | 2002-12-10 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
-
2003
- 2003-02-13 AU AU2003215190A patent/AU2003215190A1/en not_active Abandoned
- 2003-02-13 EP EP03711004A patent/EP1474535A4/en not_active Withdrawn
- 2003-02-13 WO PCT/US2003/004246 patent/WO2003070883A2/en not_active Ceased
- 2003-02-13 US US10/366,288 patent/US20030216288A1/en not_active Abandoned
- 2003-02-13 JP JP2003569776A patent/JP2005535289A/ja active Pending
-
2006
- 2006-10-11 US US11/545,891 patent/US20070031882A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522999A5 (enExample) | ||
| JP2005535289A5 (enExample) | ||
| KR20230023647A (ko) | 샘플에서 상이한 분석물 및 분석물의 상이한 하위군/변형을 검출하기 위한 멀티플렉스 방법 | |
| JP2006500949A5 (enExample) | ||
| JP2008249727A5 (enExample) | ||
| JP2002522009A5 (enExample) | ||
| JP2009502116A5 (enExample) | ||
| JP2008295444A5 (enExample) | ||
| JP2006500948A5 (enExample) | ||
| JP2004512022A5 (enExample) | ||
| RU2009135270A (ru) | Способы выявления воспалительного заболевания кишечника | |
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| JP2005514923A5 (enExample) | ||
| JP2005511023A5 (enExample) | ||
| JP2005525112A5 (enExample) | ||
| JP2010502192A5 (enExample) | ||
| JP2005516604A5 (enExample) | ||
| JP2006503575A5 (enExample) | ||
| JP2005508169A5 (enExample) | ||
| MX9709338A (es) | Receptor de transmembrana-siete de tipo c5a. | |
| JP2006501465A5 (enExample) | ||
| JP2005512528A5 (enExample) | ||
| JP2005514013A5 (enExample) | ||
| JP2005507651A5 (enExample) | ||
| JP2005514940A5 (enExample) |